-
GLI2–PRDX1 Axis Drives Ferroptosis Resistance
2026-09-18
The 2026 reference study identifies GLI2 as a transcriptional driver of ferroptosis resistance in bladder cancer through upregulation of PRDX1. Its perturbation, chromatin, transcriptomic, and rescue experiments connect this axis to malignant progression and cisplatin sensitivity, providing a mechanistic framework for chemotherapy-oriented cancer research.
-
Ibotenic Acid: NMDA Agonist Workflow Guide
2026-09-18
This practical guide shows how to use Ibotenic acid as a controlled neuroscience research tool for glutamatergic signaling studies, neurotoxicity profiling, and neurodegenerative disease model development. It translates recent dose- and time-dependent mouse findings into assay planning, sample handling, and troubleshooting decisions.
-
Amyloid β-Peptide (1-42): Microglial Assays
2026-09-17
Use Amyloid β-Peptide (1-42) to build two complementary Alzheimer’s disease models: a neuronal injury assay and a microglial migration, uptake, and clearance workflow. The key advantage is mechanistic resolution—aggregation state, extracellular nucleotide signaling, and P2Y2-dependent Aβ42 handling can be tested separately rather than treated as one nonspecific toxicity endpoint.
-
Palonosetron and Chemotherapy-Induced Nausea
2026-09-17
Ruhlmann and Herrstedt’s drug profile examines whether palonosetron’s distinctive receptor pharmacology translates into better prevention of chemotherapy-induced nausea and vomiting than earlier 5-HT3 antagonists. Its practical contribution is a structured comparison of preclinical evidence, registration trials, and post-registration experience, with particular attention to acute versus delayed symptoms, nausea control, and tolerability.
-
Dacarbazine in Cancer Response Assays
2026-09-16
Use Dacarbazine to model DNA-damaging chemotherapy in malignant melanoma, Hodgkin lymphoma, and sarcoma research while separating growth arrest from true cell killing. This workflow combines controlled exposure, orthogonal viability measurements, and time-aware interpretation to produce more informative response profiles than a single endpoint.
-
Cholesterol Workflows for mRNA-LNP Research
2026-09-16
Learn how Cholesterol supports reproducible lipid nanoparticle assembly, membrane fluidity assays, and localized mRNA delivery research. This workflow translates bladder cancer findings into practical formulation, quality-control, and troubleshooting steps while distinguishing published evidence from experimental starting points.
-
VX-661: F508del CFTR Corrector Guide
2026-09-15
VX-661 is a small-molecule F508del CFTR corrector that supports mutant CFTR folding, trafficking, and cell-surface expression. Its correction activity differs from VX-770 potentiation and depends on assay conditions, variant context, and cellular proteostasis.
-
Mitoxantrone HCl: DNA Damage Assay Workflows
2026-09-15
Build reproducible DNA-damage, apoptosis, and cell-viability experiments with Mitoxantrone HCl while separating canonical Topo-II effects from emerging ERα allosteric activity. Practical preparation guidance, assay controls, and troubleshooting help translate this compound into leukemia, stem-cell, multiple sclerosis, and solid-tumor research workflows.
-
SARS-CoV-2 Release Factors Revealed by RNAi Screening
2026-09-14
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measured SARS-CoV-2 production at multiple stages, helping identify host factors involved beyond early replication. The study highlights Rab11a-mediated vesicular transport and CDK9-linked cargo delivery as experimentally supported determinants of viral release, while also defining important boundaries for translating kinase-inhibitor findings into antiviral research.
-
Topological Stress and PML-Nucleolar Compartments
2026-09-14
Urbancokova and colleagues show that persistent ribosomal DNA lesions, rather than generic genotoxic stress alone, drive PML-nucleolar compartment formation through topological stress, RNA polymerase I inhibition, and incomplete homologous recombination. The study provides a mechanistic framework for connecting rDNA damage with nucleolar reorganization, cellular senescence, genome instability, and cancer biology.
-
CIP2A–PKM2 Drives Oxidative Phosphorylation in NSCLC
2026-09-13
The reference study identifies CIP2A as a metabolic regulator that shifts NSCLC cells from glycolysis toward oxidative phosphorylation by promoting PKM2 tetramer formation and mitochondrial localization. Its findings connect PKM2 serine 287 phosphorylation, Bcl2 signaling, and tumor-cell fitness, while supporting combined targeting of CIP2A and glycolysis as a research strategy.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-12
The reference study introduces patient-derived gastric cancer assembloids that combine tumor organoids with stromal cell subpopulations isolated from the same tumor. By preserving epithelial–stromal interactions, the model captures clinically relevant changes in gene expression and drug sensitivity, supporting more informative preclinical oncology research and personalized treatment studies.
-
Streptavidin-Cy3 for Microrobot Assays
2026-09-11
Use Streptavidin-Cy3 to convert biotin-tagged antibodies, proteins, and nucleic acids into spatially resolved fluorescence readouts for biohybrid microrobot research. This practical guide connects labeling chemistry with matrix-penetration assays, tumor-spheroid imaging, flow cytometry, and troubleshooting controls.
-
Aclacinomycin A and Persistent rDNA Stress
2026-09-11
Aclacinomycin A, or Aclarubicin, is more than a cytotoxic anthracycline: its combined topoisomerase I/II activity provides a practical way to interrogate persistent DNA lesions, nucleolar stress, and apoptosis. This article connects the compound’s established pharmacology with evidence that unresolved ribosomal DNA damage can drive PML-nucleolar associations, while defining the validation steps needed before translating that model into biomarker or therapeutic hypotheses.
-
CIP2A, PKM2 Tetramers, and NSCLC Oxidative Metabolism
2026-09-10
The reference study identifies CIP2A as a metabolic regulator in non-small cell lung cancer, showing that it binds PKM2, promotes PKM2 tetramer formation through S287 phosphorylation, and redirects metabolism toward mitochondrial oxidative phosphorylation. Its mechanistic and in vivo findings support investigating CIP2A alongside glycolytic dependence as a context-specific strategy in NSCLC research, while also highlighting the limits of extending these results to untested drug combinations.